The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum
© Chotivanich et al.; licensee BioMed Central Ltd. 2012
Received: 30 December 2011
Accepted: 25 April 2012
Published: 28 May 2012
Lumefantrine and atovaquone are highly lipophilic anti-malarial drugs. As a consequence absorption is increased when the drugs are taken together with a fatty meal, but the free fraction of active drug decreases in the presence of triglyceride-rich plasma lipoproteins. In this study, the consequences of lipidaemia on anti-malarial drug efficacy were assessed in vitro.
Serum was obtained from non-immune volunteers under fasting conditions and after ingestion of a high fat meal and used in standard Plasmodium falciparum in-vitro susceptibility assays. Anti-malarial drugs, including lumefantrine, atovaquone and chloroquine in five-fold dilutions (range 0.05 ng/ml – 1 ug/mL) were diluted in culture medium supplemented with fasting or post-prandial 10% donor serum. The in-vitro drug susceptibility of parasite isolates was determined using the 3H-hypoxanthine uptake inhibition method and expressed as the concentration which gave 50% inhibition of hypoxanthine uptake (IC50).
Doubling plasma triglyceride concentrations (from 160 mg/dL to 320 mg/dL), resulted in an approximate doubling of the IC50 for lumefantrine (191 ng/mL to 465 ng/mL, P < 0.01) and a 20-fold increase in the IC50 for atovaquone (0.5 ng/mL to 12 ng/ml; P < 0.01). In contrast, susceptibility to the hydrophilic anti-malarial chloroquine did not change in relation to triglyceride content of the medium.
Lipidaemia reduces the anti-malarial activity of lipophilic anti-malarial drugs. This is an important confounder in laboratory in vitro testing and it could have therapeutic relevance.
Malaria remains one of the most important diseases in the tropical world. The main threat for malaria control is the emergence and spread of insecticide resistance in vector mosquitoes and anti-malarial drug resistance in malaria parasites. Resistance of Plasmodium falciparum to chloroquine and sulphadoxine-pyrimethamine arose in SE Asia and has spread subsequently to Africa resulting in the deaths of millions of children [1, 2]. Resistance of Plasmodium vivax to chloroquine and pyrimethamine has also been reported in many parts of the world [3–7]. An important driver for both the emergence and spread of anti-malarial drug resistance is underdosing of anti-malarials . Underdosing in young children and pregnant women is common, because blood concentrations of several anti-malarial drugs are significantly lower compared to those in non-pregnant adults . Deployment of substandard quality or counterfeit drugs is another important contributor, although difficult to quantify . Pharmacokinetic variability is a major confounder resulting in low plasma concentrations despite taking the correct dose of a quality assured drug.
Anti-malarial drugs bind variably to plasma constituents and blood cells. Partioning of drugs in the blood may affect their access to malaria parasites. Atovaquone and lumefantrine are both highly effective lipophilic anti-malarial drugs. They are used as fixed dose combinations as atovaquone-proguanil and artemether-lumefantrine, respectively. Atovaquone-proguanil is used mainly as a chemoprophylactic  and artemether-lumefantrine is the most widely used artemisinin combination treatment of uncomplicated falciparum malaria.
Atovaquone is a hydroxynaphthoquinone, with a partition coefficient (log P) of 5.1. When given alone it rapidly leads to drug resistance, since single point mutations in the cytochrome B gene of P. falciparum can confer up to a 10,000 fold reduction in sensitivity to the drug . Atovaquone is, therefore, only deployed in combination with proguanil (Malarone R), which has a synergistic effect with atovaquone and also provides some protection against the emergence of drug resistance.
Lumefantrine is an aryl-aminoalcohol, with a similar mechanism of action to that of quinine, mefloquine, and halofantrine. It is highly lipophilic with very high (98%) binding to lipoproteins and fat in plasma. Absorption of atovaquone and lumefantrine are both increased when the drugs are taken with fat, which is the current recommendation [13–16].
However, the increase in drug absorption with a fatty meal might be offset, at least temporarily, by a reduction in the free fraction of the plasma concentration of the drug since the fatty meal will increase the concentration of plasma lipids leading to increased drug partitioning to the plasma fraction. It is not known whether this has pharmacodynamic consequences. Whether the parasiticidal activity of these lipophilic anti-malarial drugs might be affected by the concentration of lipids present in the culture medium was therefore investigated.
This study was approved by the Ethics committee of the Faculty of Tropical Medicine, Mahidol University (MUTU2006-032). Written informed consent forms were signed by the volunteers as well as patients before recruitment into this study.
Blood (20 mL) was taken from three healthy volunteer subjects (N = 3) after an overnight fast and also at 2 and 4 hours after consuming a meal containing more than 50g fat (a Mac Donald’s BigMac and a tall portion of French fries). Blood samples were centrifuged at 800 g for 5 minutes. Serum was collected, inactivated at 56°C in a water bath and kept at 30°C until use. Triglyceride levels in serum and in the culture medium were determined by an automated biochemical analyser (Cobas 501, Rocse. Switzerland).
Preparation of drugs
Triplicate 96 well plates, pre-coated with anti-malarial drugs were prepared as follows: lumefantrine (1 mg/mL in linoleic acid: 100% ethanol, 1:1) and atovaquone (1 mg/mL in 100% ethanol) in five-fold dilutions (range 0.05 ng/ml – 1 μg/mL) as described previously [17, 18]. Drugs were diluted in culture medium supplemented with fasting or post-prandial 10% donor serum. The hydrophilic anti-malarial chloroquine (range 0.05 ng/ml – 1 μg/mL) was used as a negative control.
In vitro efficacy assessment
Plasmodium falciparum laboratory strain (TM267 from Thailand) and ten P. falciparum parasites isolated from patients who visited Mae Sot Hospital, Tak, Thailand, were cultured using standard procedures . In vitro drug sensitivity testing also followed standard methods. Briefly, each well contained an aliquot (100 μL) of culture, and 100 μL of red cell suspension (final haematocrit 5%) with a 1% ring stage parasitaemia. Parasites were incubated at 37°C and 5% CO2 for 24 hours, after which 85 μL of medium was removed and refreshed by replacement of an equal volume of anti-malarial drug supplemented medium. 3H-hypoxanthine (stock = 1 millicurie/mL) was added to obtain a final dilution at 100 microcurie/mL. After 48 hours of further incubation, cells were harvested and incorporation of hypoxanthine was assessed in a beta-counter. The level of hypoxanthine uptake was determined as a measure of schizont development. The 50% inhibitory concentration (IC50), (the concentration which gave 50% inhibition of hypoxanthine uptake) was calculated from the sigmoid fitted curve, using Winnonlin computer software version 5.3 (Pharsight, USA). The IC50 values between experimental conditions were compared using the Mann- Whitney U Test. Correlations between the IC50 and triglyceride concentrations in the culture medium were calculated according to the methods of Pearson and Spearman.
50% Inhibition concentrations (IC 50) (ng/mL) of lumefantrine, atovaquone and chloroquine under different culture conditions: using medium supplemented with 10% serum obtained from a fasting donor (‘fasting’) or obtained 2 hours after ingestion of a fatty meal (‘2 hours’)
Serum used in culture medium
IC 50 (ng/mL)(Mean ± SD)
191 ± 53
465 ± 34*
0.5 ± 0.3
12 ± 6*
94 ± 39
94 ± 14
The in vitro anti-malarial drug activitiesof lumefantrine and atovaquone depend on the concentrations of lipid in the culture medium. The lack of any effect of post-prandial serum on the in vitro activity of chloroquine argues against any non-specific anti-malarial effect related to the high protein high fat meal. The decrease in anti-malarial drug activity of atovaquone and lumefantrine in the presence of triglyceride rich lipoproteins presumably reflects increased partitioning to this fraction and a reduced unbound fraction of the lipophilic drugs available to access the parasitized erythrocyte. Increased partitioning to the lipid fraction therefore reduced biological activity. Similar results have been reported for halofantrine, which is also highly lipophilic . The administration of halofantrine with food increases its absorption, and may lead to excessively high plasma halofantrine concentration and cardiac toxicity . Acute malaria also induces changes in plasma lipoprotein profiles . These factors may affect the pharmacokinetic and the pharmacodynamic profiles of these lipophilic anti-malarial drugs.
Artemether-lumefantrine is highly effective treatment of multi-drug resistant falciparum malaria [23, 24] and has become the most widely used ACT in the world. Both artemether and lumefantrine absorbtion are increased by fats although the effect on lumefantrine is greater. As a result it is recommended that lumefantrine should be taken together with fat, although a relatively small quantity (1.2 g) is necessary to achieve 90% of the maximum effect . As the initial anti-parasitic effects are mediated mainly by the artemether component, these findings of reduced lumefantrine activity in lipaemic blood are unlikely to be of therapeutic relevance to the initial response. However anti-malarial efficacy during the terminal elimination phase, when plasma concentrations of the lumefantrine are low and patients resume their normal diet, may be affected by dietary fat intake. For atovaquone-proguanil, which is mainly used as a prophylactic drug, efficacy in hyperlipidaemic travellers might be compromised. The transient elevations in triglycerides that follow meals are unlikely to affect anti-malarial activity greatly. The reduction in anti-malarial activity would be greatest in patients with persistently elevated plasma triglycerides from conditions which are common in travelers such as hyperlipoproteinaemia, diabetes, and the metabolic syndrome. Patients receiving anti-retroviral drugs may also have sustained hypertriglyceridaemia and they too might have anti-malarial efficacy compromised. Conversely atorvastatin, which is widely used in the treatment of hypercholesterolaemia, has significant anti-malarial properties . Further studies to determine the therapeutic relevance of these observations are warranted.
In vitro tests are used to monitor anti-malarial drug susceptibility. These data suggest that post-prandial or hyperlipidaemic blood or serum samples may not be appropriate for in vitro testing of lipophilic anti-malarials. Lipidaemia may contribute to variance in susceptibility testing and confound assessments of resistance.
This work was supported by the Thailand Research Fund (Grant DIG 5180016), The Wellcome Trust-Mahidol University Oxford Tropical Medicine Research Programme funded by the Wellcome Trust of Great Britain, and the Faculty of Tropical Medicine, Mahidol University. We thank all staff and nurses ofthe Hospital for Tropical Diseases, Bangkok. and the staff of the Department of Parasitology, Pramongkutklao College of Medicine, Bangkok for their help and technical support.
- Anderson TJ, Roper C: The origins and spread of antimalarial drug resistance: lessons for policy makers. Acta Trop. 2005, 94: 269-280. 10.1016/j.actatropica.2005.04.010.View ArticlePubMedGoogle Scholar
- White NJ: Antimalarial drug resistance. J Clin Invest. 2004, 113: 1084-1092.PubMed CentralView ArticlePubMedGoogle Scholar
- Schuurkamp GJ, Spicer PE, Kereu RK, Bulungol PK, Rieckmann KH: Chloroquine-resistant Plasmodium vivax in Papua New Guinea. Trans R Soc Trop Med Hyg. 1992, 86: 121-122. 10.1016/0035-9203(92)90531-G.View ArticlePubMedGoogle Scholar
- Baird JK, Sustriayu Nalim MF, Basri H, Masbar S, Leksana B, Tjitra E, Dewi RM, Khairani M, Wignall FS: Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg. 1996, 90: 409-411. 10.1016/S0035-9203(96)90526-X.View ArticlePubMedGoogle Scholar
- Soto J, Toledo J, Gutierrez P, Luzz M, Llinas N, Cedeño N, Dunne M, Berman J: Plasmodium vivax clinically resistant to chloroquine in Colombia. Am J Trop Med Hyg. 2001, 65: 90-93.PubMedGoogle Scholar
- Dua VK, Kar PK, Sharma VP: Chloroquine resistant Plasmodium vivax malaria in India. Trop Med Int Health. 1996, 1: 816-819.View ArticlePubMedGoogle Scholar
- Pukrittayakamee S, Imwong M, Looareesuwan S, White NJ: Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop. 2004, 89: 351-356. 10.1016/j.actatropica.2003.10.012.View ArticlePubMedGoogle Scholar
- White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ, Day NP: Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J. 2009, 8: 253-10.1186/1475-2875-8-253.PubMed CentralView ArticlePubMedGoogle Scholar
- Barnes KI, Watkins WM, White NJ: Antimalarial dosing regimens and drug resistance. Trends Parasitol. 2008, 24: 127-134. 10.1016/j.pt.2007.11.008.View ArticlePubMedGoogle Scholar
- Newton PN, Fernández FM, Plançon A, Mildenhall DC, Green MD, Ziyong L, Christophel EM, Phanouvong S, Howells S, McIntosh E, Laurin P, Blum N, Hampton CY, Faure K, Nyadong L, Soong CW, Santoso B, Zhiguang W, Newton J, Palmer K: A collaborative epidemiological investigation into the criminal fake artesunatetrade in South East Asia. PLoS Med. 2008, 5: e32-10.1371/journal.pmed.0050032.PubMed CentralView ArticlePubMedGoogle Scholar
- Lell B, Luckner D, Ndjavé M, Scott T, Kremsner PG: Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet. 1998, 351: 709-713. 10.1016/S0140-6736(97)09222-2.View ArticlePubMedGoogle Scholar
- Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q: Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother. 2000, 44: 2100-2108. 10.1128/AAC.44.8.2100-2108.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Meire H, Peck RW, Ridout G, Posner J: Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol. 1994, 37: 13-20. 10.1111/j.1365-2125.1994.tb04232.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Freeman CD, Klutman NE, Lamp KC, Dall LH, Strayer AH: Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother. 1998, 32: 1004-1007. 10.1345/aph.17464.View ArticlePubMedGoogle Scholar
- Schmidt LE, Dalhoff K: Food-drug interactions. Drugs. 2002, 62: 1481-1502. 10.2165/00003495-200262100-00005.View ArticlePubMedGoogle Scholar
- Ashley EA, Stepniewska K, Lindegårdh N, Annerberg A, Kham A, Brockman A, Singhasivanon P, White NJ, Nosten F: How much fat is necessary to optimize lumefantrine oral bioavailability?. Trop Med Int Health. 2007, 12: 195-200. 10.1111/j.1365-3156.2006.01784.x.View ArticlePubMedGoogle Scholar
- Basco LK, Bickii J, Ringwald P: In vitro activity of lumefantrine (Benflumetol) against clinical isolates of Plasmodium falciparum in Yaounde’, Cameroon. Antimicrob Agents Chemother. 1998, 42: 2347-2351.PubMed CentralPubMedGoogle Scholar
- Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, Sookto P, Wimonwattrawatee T, Looareesuwan S, White NJ, Nosten F: Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg. 2000, 94: 537-544. 10.1016/S0035-9203(00)90080-4.PubMed CentralView ArticlePubMedGoogle Scholar
- Trager W, Jensen JB: Human malaria parasites in continuous culture. Science. 1976, 193: 673-675. 10.1126/science.781840.View ArticlePubMedGoogle Scholar
- Humberstone AJ, Cowman AF, Horton J, Charman WN: Effect of altered serum lipid concentrations on the IC50 of halofantrine against Plasmodium falciparum. J Pharm Sci. 1998, 87: 256-258. 10.1021/js970279q.View ArticlePubMedGoogle Scholar
- Mohanty S, Mishra SK, Das BS, Satpathy SK, Mohanty D, Patnaik JK, Bose TK: Altered plasma lipid pattern in falciparum malaria. Ann Trop Med Parasitol. 1992, 86: 601-606.PubMedGoogle Scholar
- Monlun E, Le Metayer P, Szwandt S, Neau D, Longy-Boursier M, Horton J, Le Bras M: Cardiac complications of halofantrine: a prospective study of 20 patients. Trans R Soc Trop Med Hyg. 1995, 89: 430-433. 10.1016/0035-9203(95)90041-1.View ArticlePubMedGoogle Scholar
- van Vugt M, Brockman A, Gemperli B, Luxemburger C, Gathmann I, Royce C, Slight T, Looareesuwan S, White NJ, Nosten F: Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother. 1998, 42: 135-139.PubMed CentralPubMedGoogle Scholar
- van Vugt MV, Wilairatana P, Gemperli B, Gathmam I, Phipum L, Brockman A, Luxemburger C, White NJ, Nosten F, Looareesuwan S: Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg. 1999, 60: 936-942.Google Scholar
- Parquet V, Briolant S, Torrentino-Madamet M, Henry M, Almeras L, Amalvict R, Baret E, Fusaï T, Rogier C, Pradines B: Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2009, 53: 2248-2252. 10.1128/AAC.01462-08.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.